Spinal Manipulation and Patient Self-Management for Preventing Acute to Chronic Back Pain

Overview

This is a study of adults with acute low back pain flare-up at risk of becoming chronic and disabling. The study tests how well spinal manipulation and guided selfcare work compared to standard medical care. The treatments last up to eight weeks and participants will be followed for one year.

Full Title of Study: “Spinal Manipulation and Patient Self-Management for Preventing Acute to Chronic Back”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Factorial Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Investigator, Outcomes Assessor)
  • Study Primary Completion Date: June 2024

Detailed Description

The long-term goal is to reduce overall low back pain (LBP) burden by evaluating, first-line, non-drug treatment strategies that address the biological, psychological and social aspects of acute LBP and prevent transition to chronic back pain. The study will also assess barriers and facilitators that impact future implementation of the non-drug treatments into clinical practice. The US faces an unprecedented pain management crisis. LBP is the most common chronic pain condition in adults and one of the leading causes of disability worldwide. Guidelines have recommended non-drug treatments like spinal manipulation and behavioral and selfcare approaches for LBP for nearly a decade, yet uptake and adherence has been poor. Little is known about the role of these treatments in the secondary prevention of chronic LBP, especially for patients at risk of developing severe low back pain. Due to high societal costs, and side effects of commonly used drug treatments, including opioids, there is a critical need for research on how well non-drug treatments work for preventing serious chronic LBP.

Interventions

  • Behavioral: Supported-Self Management (SSM)
    • Provides low back pain sufferers opportunities to develop the capacity and motivation to self-manage their pain in an adaptive manner. This includes psychological/behavioral strategies, mind-body approaches, lifestyle advice, pain education and pain coping.
  • Other: Spinal Manipulation Therapy (SMT)
    • SMT will address the biological and physical aspects of low back pain (e.g. spinal dysfunction) with the intention of restoring maximum movement and functional ability of the spine.
  • Combination Product: SMT + SSM
    • Combination Treatment
  • Drug: Standard Medical Care (SMC)
    • Guideline based medical care informed by the American College of Physicians’ guidelines on noninvasive treatment for low back pain.

Arms, Groups and Cohorts

  • Experimental: Supported-Self management (SSM)
    • Supported-Self management
  • Experimental: Spinal Manipulation Therapy (SMT)
    • Spinal Manipulation Therapy
  • Experimental: SMT + SSM
    • Spinal Manipulation Therapy + Supported Self-Management
  • Active Comparator: Standard Medical Care (SMC)
    • Standard Medical Care

Clinical Trial Outcome Measures

Primary Measures

  • Average pain intensity over one year post-randomization
    • Time Frame: Weekly from enrollment – 52 weeks
    • Measured using the 0-10 numerical rating scale (0=no LBP, 10=the worst LBP possible).
  • Average disability over one year post-randomization
    • Time Frame: Measured monthly from enrollment – 52 weeks
    • Measured using the Roland-Morris Disability Questionnaire (RMDQ), a 24-item questionnaire that measures the degree to which a low back problem restricts daily activities.
  • Prevention of chronic low back pain (LBP) that is impactful at 10-12 months follow-up
    • Time Frame: Months 10 -12
    • Measured by the LBP impact scale which includes measures of pain intensity, pain interference, and physical function from the PROMIS-29 Profile v2.0. The scale ranges from 8 (least impact) to 50 (greatest impact).

Secondary Measures

  • Recovery from acute/sub-acute low back pain
    • Time Frame: 6 months
    • Measured by the proportion of patients with scores of 0 on the 0-10 pain numeric rating scale (NRS) and a score of less than or equal to 2 on the Roland-Morris Disability Questionnaire (RMDQ), a 24-item questionnaire that measures the degree to which a low back problem restricts daily activities.
  • Patient-Reported Outcomes Measurement Information System (PROMIS-29)
    • Time Frame: Measured monthly from enrollment – 52 weeks
    • Includes pain interference with normal activities, physical function, anxiety, depression, fatigue, sleep disturbance and the ability to participate in social roles and activities.
  • Low Back Pain Frequency
    • Time Frame: Weekly from enrollment – 52 weeks
    • Participants report the number of days low back pain has been a problem in the past 7 days.
  • Healthcare Utilization
    • Time Frame: Measured monthly from enrollment – 52 weeks
    • Includes provider visits, emergency department visits, diagnostic imaging scans, hospitalizations, injections and surgical procedures.
  • Medication Use
    • Time Frame: Measured monthly from enrollment – 52 weeks
    • Over the counter and prescription medication use for low back pain including class and frequency by class.
  • Productivity loss
    • Time Frame: Measured monthly from enrollment – 52 weeks
    • Missed work and reduced productivity while at work will be assessed using questions from the Institute for Medical Technology Assessment’s productivity cost questionnaire.
  • Risk factors for transitioning to chronic low back pain
    • Time Frame: Baseline, 2, 6, 12 months
    • Measured using the STarT Back Screening Tool.
  • Global Improvement
    • Time Frame: Baseline, 2, 6, 12 months
    • Measured using a 9-point scale (completely recovered to vastly worse)
  • Patient Satisfaction with Treatment
    • Time Frame: Baseline, 2, 6, 12 months
    • Measured using a 7-point Likert scale (completely satisfied to completely dissatisfied)
  • Healing Encounters and Attitudes Lists (HEAL)
    • Time Frame: Baseline, 2 weeks, and 1, 2, 6, 12 months
    • Includes patient-provider connection (7-item), healthcare environment (6-item), positive outlook (6-item) and treatment expectancy (6-item) from the HEAL measured on a 5-point scale (not at all to very much)
  • Intervention Barriers
    • Time Frame: Screening, baseline, 2, 6, 12 months
    • This qualitative assessment explores barriers to participation in the intervention using open ended questions in an electronic survey.
  • Intervention Facilitators
    • Time Frame: Screening, baseline, 2, 6, 12 months
    • This qualitative assessment explores facilitators to participation in the intervention using open ended questions in an electronic survey.
  • Covid 19 Impact
    • Time Frame: Screening, baseline, 2, 6, 12 months
    • Measured using the 7-item Pain Management Collaboratory (PMC) Coronavirus (COVID-19) Pandemic Measure
  • Telehealth Usability Questionnaire
    • Time Frame: Baseline, 1, 2 months
    • Participants’ views of the remote intervention delivery platform will be assessed using items adapted from the Telehealth Usability Questionnaire
  • Adverse Events
    • Time Frame: Measured during treatment and monthly from enrollment – 52 weeks
    • Any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome or disease which either occurs during the study, having been absent at baseline, or if present at baseline, appears to worsen.
  • Prevention of chronic low back pain (LBP)
    • Time Frame: 6, 12 Months
    • Measured by the proportion of patients in each group meeting the definition by the NIH Task Force on Research Standards for Chronic LBP (i.e., ongoing LBP on ≥50% of days over past 6 months).
  • Timed Up and Go Test
    • Time Frame: Baseline and 2 months
    • Measured by a blinded examiner, in seconds, the time taken by a person to stand up, walk a distance of 10 feet, turn, walk back to the chair and sit down again.
  • Sit-to-stand
    • Time Frame: Baseline and 2 months
    • Measured by a blinded examiner, in seconds, the amount of time a person requires to stand up and sit down from a chair 5 times without using their arms
  • The Sock Test
    • Time Frame: Baseline and 2 months
    • Measured by a blinded examiner on a scale from 0-3, with 0 being can easily grab the toes with the fingertips of both hands and 3 being can hardly, if at all, reach as far as to the malleoli.
  • Chronic Interference with Daily Activities
    • Time Frame: Baseline, 6 and 12 months
    • Assessed using “how often has low back pain interfered with your ability to do regular activities over the past 6 months?” on a 3-item scale (less than half the days in the past 6 months, at least half the days in the past 6 months, every day or nearly every day in the past 6 months).
  • Visual Trajectory for Pain
    • Time Frame: Baseline, 12 months
    • Assessed using 8 different diagrams describing back pain change over the last 12 months
  • Quebec Task Force
    • Time Frame: Baseline, 2 months
    • Measured by a blinded examiner who will classify the participant’s spinal disorder as 0) no pain; 1) pain without radiation; 2) pain with radiation to the proximal extremity; 3) pain with radiation to the distal extremity; 4) pain with radiation to the extremity and neurologic signs.

Participating in This Clinical Trial

Inclusion Criteria

  • At least 18 years of age – Acute or sub-acute low back pain – Average low back pain severity ≥3 on the 0-10 numerical rating scale over 7 days – Medium or high risk for persistent disabling back pain according to the STarT Back screening tool – Ability to read and write fluently in English Exclusion Criteria:

  • Non-mechanical causes of low back pain – Contraindications to study treatments (e.g,. surgical fusion of lumbar spine) – Active management of current episode of low back pain by another healthcare provider – Serious co-morbid health condition that either requires medical attention or has a risk for general health decline over the next year – Pregnancy, current or planned during study period and nursing mothers – Inability or unwillingness to give written informed consent

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University of Minnesota
  • Collaborator
    • University of Pittsburgh
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Gert Bronfort, PhD, DC, Principal Investigator, University of Minnesota

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.